STAT+: Health care industry fights back against crackdowns on health data tracking
Wherever you go on the internet, trackers follow. These ubiquitous bits of code, invisibly embedded…
Category: STAT+
STAT+: Biden administration asks judge to toss out Humana’s Medicare Advantage audit lawsuit
The Department of Justice has asked a federal judge to dismiss a lawsuit brought by…
STAT+: Apple pauses sales of latest watches in the US after ITC decision
Apple is temporarily pulling certain Apple Watches from the U.S. market to comply with an…
STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal
The closely watched gene editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with…
STAT+: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds
As more data emerges that obesity drugs like Wegovy can reduce complications from heart and…
STAT+: Pharmalittle: Illumina will divest Grail after court finds deal was anti-competitive; FDA found problems at Moderna facility
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study
Structure Therapeutics said Monday that its experimental GLP-1 pill demonstrated a 1% lowering of blood…
STAT+: Here are the best biopharma CEOs of 2023
It’s that time of the year again when I recognize the Best Biopharma CEO of…
STAT+: ‘We’ve exhausted all avenues’: A small biotech may give up on its ultra-rare disease drug over frustration with FDA
Jamie Dubuque faces the future with a mixture of gratitude and trepidation. Her son, Declan,…
STAT+: New Jersey’s telehealth restrictions cut off access to lifesaving care, lawsuit alleges
Since states started rolling back pandemic-inspired flexibilities that allowed physicians to easily practice telehealth across…
STAT+: Illumina says it will divest Grail, starting a closing chapter for a disastrous deal
Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail,…
STAT+: The biggest health care deals of 2023
Every year, the health care industry behaves more and more like a balloon: Squeeze one…
.jpg)
STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish
And so, another working week will soon draw to a close. Not a moment too…
STAT+: European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy
LONDON — The world’s first medicine based on the genome-editing technology CRISPR will almost certainly…
STAT+: Sanders blames food companies for diabetes epidemic
WASHINGTON — Sen. Bernie Sanders (I-Vt.) has a new corporate target: the food industry. Sanders…
STAT+: In response to criticism, FDA publishes new database of wayward clinical trial sponsors
In a bid toward greater transparency, the U.S. Food and Drug Administration earlier this month…
STAT+: Amputees have better balance, less pain after electrical stimulation, study finds
For years, Lauren Gavron relied on oxycodone to quiet the pain in her missing lower…
STAT+: Why FDA product recalls have spiked in recent years
Either American products are getting worse, or scrutiny over their safety is getting tougher. Whichever…
STAT+: Jay Bradner, former Novartis research leader, to head up Amgen’s scientific efforts
Jay Bradner, a former top research leader at Novartis, is joining Amgen as its new…
STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Bankrupt Pear’s addiction treatments acquired by virtual care company
Half a year after selling its assets at bankruptcy auction, Pear Therapeutics’ most significant digital…
STAT+: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in
For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight…
Supreme court will decide abortion pill access
WASHINGTON — The Supreme Court agreed Wednesday to take on whether Americans can access a…
STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pfizer says 2024 profits will fall far below expectations
Pfizer said Wednesday that its 2024 profits would fall far below investor expectations, leading shares…
STAT+: Vertex non-opioid drug reduces chronic nerve pain in mid-stage study
Vertex Pharmaceuticals said Wednesday that an experimental drug reduced pain in people with diabetes who…
STAT+: Could sickle cell someday be treated not with CRISPR, but with a pill?
Two gene therapies were approved for sickle cell disease last week, but for many researchers…
STAT+: Maze CEO ‘personally disappointed’ in Sanofi decision to terminate partnership
When Sanofi terminated its partnership with Maze Therapeutics this week to develop an experimental drug…
STAT+: A targeted therapy shows it can offer a ‘last, great chance’ for some acute leukemia patients
SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration…
STAT+: Bone marrow transplant advance could widen use of this less buzzy cure for sickle cell disease
SAN DIEGO — The sickle cell community has for the past few days been buzzing…
STAT+: Late-stage trial supports broader use of Darzalex, blockbuster J&J multiple myeloma drug
SAN DIEGO — Johnson & Johnson’s multiple myeloma therapy, Darzalex, is already a blockbuster. Now…
STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: With big ambition — and a family name to match — Reed Jobs charts his own course in biotech
In the months after his father died of complications from pancreatic cancer, Reed Jobs found…
STAT+: UnitedHealth executive to head health insurance group AHIP
WASHINGTON — An executive at insurance giant UnitedHealth Group is slated to be the next…
STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns
In its latest bid to police the pharmaceutical industry, the U.S. Federal Trade Commission sought…
STAT+: Hot antitrust environment hangs over called-off merger between Cigna and Humana
Less than two weeks after reports surfaced saying Cigna and Humana were considering combining into…
Opinion: STAT+: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker
Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in…
STAT+: GE HealthCare CEO named chair of medical device lobby AdvaMed’s new imaging division
AdvaMed named Peter Arduini, CEO of GE HealthCare, chair of its board of directors on…
STAT+: NEJM aims to hold AI to account with new publication
One of the most prestigious names in medical publishing is going all in on artificial…
STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds
During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical…
STAT+: Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year
Amid fears of superbugs, the sale of medically important antibiotics given to food-producing livestock rose…
STAT+: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale
The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been…
STAT+: Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers
SAN DIEGO — For decades, the biotech industry has tried — and repeatedly failed —…
STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk
Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could…
STAT+: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH
SAN DIEGO — News of the Food and Drug Administration’s historic approval of the first…
STAT+: CAR-T, recently used in a lupus patient, helps other autoimmune patients, too, in small study
SAN DIEGO — When the first lupus patient received CAR-T therapy, researchers watched in amazement as…
STAT+: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first published case
SAN DIEGO — Researchers on Saturday presented an unusual case of a T cell lymphoma…
STAT+: Vertex gets a win as Colorado board leaves cystic fibrosis drug off a list of unaffordable medicines
In a win for Vertex Pharmaceuticals, a Colorado state board voted not to place the…
STAT+: Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy
The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell…